Natural anti-Gal antibody (anti-Gal)

Natural anti-Gal antibodies are the most abundant natural antibodies in humans, constituting approximately 1% of circulating immunoglobulins (1.2.1, 1.3.1). They are produced against the alpha-gal epitope (Gal-alpha-1,3-Gal), which is present in most mammals but absent in humans, apes, and Old World monkeys due to the evolutionary inactivation of the alpha-1,3-galactosyltransferase enzyme (1.3.1, 1.4.2). These antibodies play a critical role in the hyperacute rejection of xenografts, such as pig-to-human transplants, and are the primary cause of Alpha-gal syndrome, a delayed allergic reaction to red meat triggered by tick bites (1.2.1, 1.4.3). In therapeutic contexts, anti-Gal antibodies are harnessed for cancer immunotherapy by injecting alpha-gal glycolipids into tumors to target them for destruction by the immune system (1.3.1, 1.3.4). They are also utilized in wound healing applications where alpha-gal nanoparticles recruit macrophages to injury sites (1.3.1, 1.3.2). Drugs like GAS914 have been developed to neutralize these antibodies to prevent transplant rejection, while alpha-gal-containing drugs like cetuximab can trigger adverse allergic responses in sensitized individuals (1.3.1, 1.4.3).

Other names

anti-alpha-gal antibodiesanti-Gal-alpha-1,3-Gal antibodiesxenoreactive natural antibodiesNatural anti-Gal IgG/IgM antibodies

Binding to alpha-gal epitopes (Gal-alpha-1,3-Gal) on cells or pathogens to induce complement-mediated lysis, opsonization, and recruitment of antigen-presenting cells or macrophages.